In vivo CAR-T Cell Induction

Produce CAR-T cells in the patient's body. The development of such dream-like T cell-specific genome editing technology has begun. The problem is that the efficiency of CAR-T cell production is low and there is a contradiction that the loss of immune cells in the pre-treatment to allow CAR-T cells to proliferate in the body further reduces the efficiency of CAR-T cell production.
https://miyata-bio.net/column/0000319/